The stock has a 36-month beta value of -1.98. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KALA is 5.31M, and at present, short sellers hold a 5.40% of that float. On June 04, 2025, the average trading volume of KALA was 53.17K shares.
KALA) stock’s latest price update
Kala Bio Inc (NASDAQ: KALA)’s stock price has soared by 16.36 in relation to previous closing price of 3.52. Nevertheless, the company has seen a gain of 0.74% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the Jefferies Global Healthcare Conference being held in New York, NY on Thursday, June 5, 2025 at 1:25 p.m. ET. Management will also be available for one-on-one meetings on Thursday, June 5, 2025.
KALA’s Market Performance
Kala Bio Inc (KALA) has seen a 0.74% rise in stock performance for the week, with a 9.07% gain in the past month and a -40.90% plunge in the past quarter. The volatility ratio for the week is 9.30%, and the volatility levels for the past 30 days are at 6.12% for KALA. The simple moving average for the past 20 days is 11.44% for KALA’s stock, with a -32.35% simple moving average for the past 200 days.
Analysts’ Opinion of KALA
Jefferies gave a rating of “Hold” to KALA, setting the target price at $10 in the report published on September 14th of the previous year.
KALA Trading at 1.46% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.48% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALA starting from Mark T Iwicki, who proposed sale 10,866 shares at the price of $3.74 back on Jun 03 ’25. After this action, Mark T Iwicki now owns shares of Kala Bio Inc, valued at $40,639 using the latest closing price.
Kharabi Darius, the CHIEF BUSINESS OFFICER of Kala Bio Inc, sale 2,021 shares at $7.63 during a trade that took place back on Jan 06 ’25, which means that Kharabi Darius is holding 67,807 shares at $15,420 based on the most recent closing price.
Stock Fundamentals for KALA
The total capital return value is set at -1.57. Equity return is now at value -576.46, with -70.40 for asset returns.
Based on Kala Bio Inc (KALA), the company’s capital structure generated 0.75 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at 3.02. The interest coverage ratio of the stock is -12.27.
Currently, EBITDA for the company is -40.98 million with net debt to EBITDA at 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.99.
Conclusion
To sum up, Kala Bio Inc (KALA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
